Producing more vaccines and medicines in Africa depends on more than factories. Manufacturers also need to understand regulatory requirements and have the quality of their products recognised across borders. In Kigali, two new African Medicines Agency (AMA) hubs aim to address this challenge.
In Kigali, support for manufacturers and regulators
The AMA launched its two hubs on Tuesday 27 October 2026, as part of its first working week, held in Kigali, Rwanda. A day earlier, the agency had inaugurated seven technical committees. These steps mark the gradual establishment of an African Union institution that has been operational since October 2025.
The first hub, dedicated to regulatory innovation and manufacturing readiness, is intended to facilitate exchanges between the agency, industry and innovators. Its aim is to clarify the rules expected before a medical product is submitted for assessment. The second focuses on capacity-building: it is to support regulatory authorities and professionals through cooperation and training.
For project leaders, this support can begin at an early stage. AMA expert Solomon Onen explains that the agency wants to help innovators comply with good laboratory practice and prepare the scientific dossiers needed for market access. The challenge is to better connect research, industrial development and quality control.
The arrangement does not, however, replace national authorities. The AMA’s mandate is to coordinate regulatory systems, promote joint assessments and build capacity. Decisions on marketing authorisation remain the responsibility of the competent national bodies, under the agency’s framework.
Continental ambition, practical obstacles
The African Union aims to produce 60% of the vaccines needed on the continent by 2040. This target relates specifically to vaccines. It forms part of a broader effort to develop local manufacturing of health products and reduce vulnerabilities linked to external supplies.
But production capacity alone does not guarantee that products will reach patients quickly. Different rules or procedures from one country to another can force companies to repeat some steps. This increases costs and complicates access to several markets, particularly for smaller businesses and new manufacturers.
The harmonisation sought by the AMA aims to reduce such duplication and strengthen trust between regulators. In this framework, authorities can make greater use of scientific assessments carried out by their counterparts, while retaining national responsibility. A single continent-wide authorisation has been raised by industry stakeholders as a prospect, but it should not be confused with the agency’s current coordination role.
The African Continental Free Trade Area (AfCFTA), which aims to facilitate trade between African countries, could expand manufacturers’ markets. However, trade liberalisation will not be enough without credible standards, oversight capacity and common safety requirements. The challenge is therefore twofold: to facilitate the movement of compliant products without weakening patient protection.
Different effects for different stakeholders
For manufacturers, more predictable regulatory pathways can reduce the time and cost of establishing operations in several countries. For researchers and start-ups, scientific support can help turn a discovery into an acceptable dossier. National authorities, meanwhile, will need trained staff, strong laboratories and sustainable resources to assess products.
The benefits for the public will depend on what follows: the availability, price, quality and distribution of medicines. Urban centres and large markets may attract investment first. Patients in remote areas will benefit from the new capacity only if supply chains and health services reach them too. Local production therefore does not automatically mean equitable access.
Rwanda hosts the agency and its headquarters in Kigali, but the hubs have a continental remit. Their effectiveness will be measured by the cooperation they establish between national regulators and African regional economic communities. These regional forums can help bring practices closer together and organise exchanges between authorities.
Next step: turning structures into results
The AMA has also held discussions with manufacturers and worked on a common protocol for clinical trials of vaccine candidates against the Bundibugyo strain of the Ebola virus. This work highlights the practical value of regulatory coordination in an emergency. The World Health Organization says that no vaccine is currently authorised specifically against this strain and that candidates must be assessed within a research framework.
The AMA’s inaugural week runs until 30 October 2026 in Kigali. It brings together, among others, the technical committees, national regulatory authorities and regional officials. The work and decisions that emerge will show whether the two hubs become regular tools for training, support to innovators and scientific cooperation.
At African Union level, the challenge goes beyond creating a new agency. It is about building systems capable of overseeing products, supporting local innovation and responding collectively to health emergencies. The target of producing 60% of vaccines in Africa by 2040 gives a measure of the ambition; results will now depend on the implementation of standards and investment in skills and institutions.



